Metformin lowers preterm birth risk for high-risk mothers

How the Trial Was Conducted

New research from Monash University shows that metformin, a widely used diabetes drug, can significantly reduce the chances of early and preterm births among mothers at high metabolic risk. The findings, published in the New England Journal of Medicine Evidence, suggest that this affordable, oral medication could become a routine part of prenatal care for vulnerable women.

The study focused on pregnant women with elevated metabolic risk factors, such as obesity or insulin resistance, who are more likely to experience complications including preterm delivery. Researchers found that those who took metformin during pregnancy had notably lower rates of early birth compared to those who did not. The drug works by improving insulin sensitivity and reducing inflammation, both of which play roles in maintaining healthy pregnancies.

The clinical trial enrolled hundreds of high-risk pregnant women across multiple medical centers. Participants were randomly assigned to receive either standard prenatal care alone or standard care plus metformin. The primary goal was to measure the incidence of preterm births before 34 weeks of gestation. Results showed a clear benefit: the group taking metformin had approximately 20% fewer early preterm deliveries. Researchers also noted improvements in birth weight distribution and reduced rates of gestational diabetes.

Lead author Dr. Lisa Mitchell from Monash University emphasized the global implications. „Preterm birth is a leading cause of infant mortality and long-term disability worldwide,”she said. „If we can prevent even a fraction of these cases with a safe, inexpensive drug, the public health impact is enormous.” Could This Change Prenatal Care Guidelines?

Experts believe the results may prompt updates to clinical guidelines, particularly in low-resource settings where preterm birth rates are highest. Metformin has been used safely in pregnancy for decades, primarily for women with gestational diabetes. This new evidence expands its potential role to a broader population of at-risk mothers.

Frequently Asked Questions

However, researchers caution that further studies are needed to confirm optimal dosing and to monitor long-term outcomes for both mothers and children. The team is already planning follow-up research to assess developmental milestones in babies born to mothers who took the medication.

The outlook is promising. If adopted widely, metformin supplementation could become a simple, cost-effective strategy to improve maternal and neonatal health on a global scale.

What is metformin and why is it being studied in pregnancy? Metformin is an oral medication commonly prescribed for type 2 diabetes. It helps control blood sugar by improving insulin sensitivity. In pregnancy, it may help prevent metabolic complications that lead to preterm birth.

Who qualifies as high metabolic risk? Women with conditions such as obesity, polycystic ovary syndrome, or insulin resistance are considered high risk. These factors increase the likelihood of gestational diabetes and preterm delivery.

Are there risks of taking metformin during pregnancy? Metformin has a long safety record in pregnancy. Side effects are generally mild, such as nausea or digestive upset. Doctors will monitor patients closely to ensure appropriate dosing and response.